Motive Wealth Advisors raised its position in Pfizer Inc. (NYSE:PFE – Get Rating) by 9.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,612 shares of the biopharmaceutical company’s stock after buying an additional 479 shares during the quarter. Motive Wealth Advisors’ holdings in Pfizer were worth $288,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Harbor Investment Advisory LLC boosted its position in shares of Pfizer by 3.6% during the 4th quarter. Harbor Investment Advisory LLC now owns 23,977 shares of the biopharmaceutical company’s stock worth $1,229,000 after acquiring an additional 825 shares in the last quarter. Saxon Interests Inc. lifted its position in shares of Pfizer by 12.9% during the 3rd quarter. Saxon Interests Inc. now owns 8,309 shares of the biopharmaceutical company’s stock worth $367,000 after buying an additional 951 shares during the last quarter. Platte River Wealth Advisors LLC grew its position in Pfizer by 62.8% in the third quarter. Platte River Wealth Advisors LLC now owns 12,717 shares of the biopharmaceutical company’s stock valued at $556,000 after acquiring an additional 4,905 shares during the last quarter. Accuvest Global Advisors lifted its holdings in shares of Pfizer by 16.6% in the third quarter. Accuvest Global Advisors now owns 12,994 shares of the biopharmaceutical company’s stock worth $569,000 after acquiring an additional 1,848 shares during the last quarter. Finally, Secure Asset Management LLC grew its holdings in shares of Pfizer by 3.5% during the 4th quarter. Secure Asset Management LLC now owns 15,835 shares of the biopharmaceutical company’s stock valued at $811,000 after purchasing an additional 537 shares during the last quarter. Institutional investors and hedge funds own 67.62% of the company’s stock.
Wall Street Analyst Weigh In
Several equities research analysts recently weighed in on PFE shares. Jefferies Financial Group initiated coverage on Pfizer in a report on Monday, March 6th. They set a “hold” rating and a $43.00 price objective on the stock. UBS Group set a $45.00 target price on shares of Pfizer in a research report on Tuesday, March 14th. Bank of America downgraded shares of Pfizer from a “buy” rating to a “neutral” rating and set a $60.00 price target for the company. in a research note on Wednesday, January 4th. StockNews.com initiated coverage on Pfizer in a report on Thursday, March 16th. They set a “buy” rating on the stock. Finally, JPMorgan Chase & Co. set a $45.00 price objective on Pfizer in a research report on Monday, February 27th. Eight equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average target price of $49.93.
Pfizer Stock Performance
Pfizer (NYSE:PFE – Get Rating) last announced its quarterly earnings results on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $1.03 by $0.11. Pfizer had a net margin of 31.27% and a return on equity of 42.03%. The business had revenue of $24.30 billion for the quarter, compared to analysts’ expectations of $24.40 billion. During the same quarter last year, the firm earned $1.08 EPS. The firm’s revenue for the quarter was up 1.9% compared to the same quarter last year. Analysts forecast that Pfizer Inc. will post 3.3 EPS for the current fiscal year.
Insider Transactions at Pfizer
In other news, major shareholder Pfizer Inc acquired 1,811,594 shares of Pfizer stock in a transaction on Friday, March 17th. The stock was acquired at an average cost of $2.76 per share, with a total value of $4,999,999.44. Following the transaction, the insider now owns 5,952,263 shares of the company’s stock, valued at approximately $16,428,245.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.05% of the company’s stock.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
Read More
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- MarketBeat Week in Review – 4/3 – 4/7
- Costco Sales Disappoint, Markets Are Missing This Upside Driver
- First Republic Bank Is A Speculative Play, Here’s Why
- The WD-40 Company Bottoms With Reversal In Sight
- 3 Low-Cost Stock ETFs That Are Crushing It This Year
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Get Rating).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
